Drug Search Results
More Filters [+]

FRTX-10

Alternative Names: FRTX-10, FRTX-10, FRTX-10
Latest Update: 2023-03-07
Latest Update Note: Clinical Trial Update

Product Description

FRTX-10 inhibits STING palmitoylation, thereby inhibiting the activation of STING and resulting in an efficient shutdown of the STING downstream pathway. Upon in vivo stimulation of mice with a STING agonist, oral administration of FRTX-10 was observed to reduce serum cytokine levels of IL-6 and IFN-b. (Sourced from: https://www.frtx.com/pipeline/frtx-10/)

Mechanisms of Action: STING Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Fresh Tracks Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for FRTX-10

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Autoimmune Disease Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events